Cardioversion for atrial fibrillation in current European practice: Results of the European Heart Rhythm Association survey

Europace

Volumn 15, Issue 6, 2013, Pages 915-918

  Hernández Madrid, Antonio ^a   Svendsen, Jesper Hastrup ^b,c   Lip, Gregory Y H ^d   Van Gelder, Isabelle C ^e   Dobreanu, Dan ^f   Blomstrom Lundqvist, Carina ^g  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Atrial fibrillation; Cardioversion; EHRA survey; Rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DABIGATRAN; DILTIAZEM; FLECAINIDE; LOW MOLECULAR WEIGHT HEPARIN; PROPAFENONE; RIVAROXABAN; SOTALOL; VERAPAMIL; VERNAKALANT;

ANESTHESIST; ANTICOAGULATION; CARDIOLOGIST; CARDIOVERSION; CATHETER ABLATION; CLINICAL PRACTICE; DEFIBRILLATOR; EUROPE; GENERAL ANESTHESIA; HEART ATRIUM FIBRILLATION; HUMAN; PACEMAKER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; UNIVERSITY HOSPITAL;

ANTICOAGULATION; ATRIAL FIBRILLATION; CARDIOVERSION; EHRA SURVEY; RHYTHM CONTROL;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; ELECTRIC COUNTERSHOCK; EUROPE; HEALTH CARE SURVEYS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RISK FACTORS; THROMBOEMBOLISM;

EID: 84878317255     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut143     Document Type: Review

References (15)

1. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
2. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.
3. VanGelder I, Hagens V, Bosker Hm, Kingma JH, Kamp O, Kingma T et al. Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-50.
4. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL et al. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1509-13.
5. Neumann T, Erdogan A, Reiner C, Siemon G, Kurzidim K, Berkowitsch A et al. HF ambulatory electrocardioversion of atrial fibrillation by means of biphasic versus monophasic shock delivery. A prospective randomized study. Z Kardiol 2004;93: 381-7.
6. Ricard P, Levy S, Boccara G, Lakhal E, Bardy G. External cardioversion of atrial fibrillation: comparison of biphasic vs. monophasic waveform shocks. Europace 2001;3: 96e9.
7. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrialfibril-lation: a randomised trial. Lancet 2002;360:1275-9.
8. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ et al. Clinical correlatesof immediate success and outcome at1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 2012;14:666-74.
9. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution ofthe European Heart Rhythm Association. Euro-pace 2012;14:1385-413.
10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, ErnstS et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology. Europace 2010;12:1360-420.
11. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-21.
12. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L et al. Outpatient treatment of recent-onset atrial fibrillation with the 'pill-in-the-pocket' approach. N Engl J Med 2004;351:2384-91.
13. Arias MA, Casares-Medrano J, Pachón M, Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev Esp Cardiol 2012;65:489.
14. Klein A, Grimm R, Murray D, Apperson-Hansen C, Asinger RW, Black LW et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
15. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabi-gatran vs. warfarininpatients with atrialfibrillation:an analysisof patients undergoing cardioversion. Circulation 2011;123:131-6.